High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant (ATLL-HR-01)
Observational Prospective Study, Evaluating the Standard of Care as Recommend by International Consensus With Zidovudine-Pegylated Interferon +/-Polychemotherapy in High Risk Adult-T-cell Lymphoma/Leukaemia (T-cell Lymphoma/Leukaemia) Followed by Allogeneic Transplant Among Eligible Patients Younger Than 65 Years Old
Sponsor: University Hospital Center of Martinique
Listed as NCT01941680, this observational or N/A phase trial focuses on Leukaemia and T-cell Lymphoma and remains completed. Sponsored by University Hospital Center of Martinique, it has been updated 11 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Sep 2021 — Jul 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Mar 2021 — Sep 2021 [monthly]
Active Not Recruiting
▶ Show 6 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting
-
Aug 2019 — Jan 2021 [monthly]
Active Not Recruiting
-
Jun 2018 — Aug 2019 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
May 2017 — Apr 2018 [monthly]
Recruiting NA
-
Jan 2017 — May 2017 [monthly]
Recruiting NA
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital Center of Martinique
For direct contact, visit the study record on ClinicalTrials.gov .